Đang chuẩn bị liên kết để tải về tài liệu:
Pharmaceutical Substances Syntheses, Patents, Applications - Part 94

Pharmaceutical Substances Syntheses, Patents, Applications - Part 94. Reference containing a collection of 2267 active pharmaceutical ingredients, including those launched recently. Listed alphabetically according to their INNs and established a link between INNs, structure, synthesis and production processes, patent and literature situation, medical use, and trade names. For pharmacists and researchers | Formebolone F 931 Formebolone Formyldienolone ATC A14 Use anabolic anti-inflammatory RN 2454-11-7 MF C21H28O4 MW 344.45 EINECS 219-523-2 LD50 187 mg kg M i.p. 293 mg kg M S.C. 104 mg kg R i.p. 270 mg kg R s.c. CN 11 a 17ß -11 17-dihydroxy-17-methyl-3-oxoandrosta-1 4-diene-2-carboxaldehyde Me 11 a 170-dihydroxy-17 - methyl-3-oxo-4-ondrostene OHC -0 CH3 NqOCH-j 1 ethyl formate . ci Cl 1 ------ ------------- 2.3- dichioro- 5 6-dicyano- 1.4- benzoquinone Reference s DE 1 618 616 LPB Braglia appl. 8.2.1967 . GB 1 168 931 LPB Braglia valid from 20.1.1967 . Formulations amp. 2 ml 2 ml tabl. 5 mg Trade Name s I Esiclene LPB Formes tane 4-HAD 4-DHA ATC L02B G03BA Use aromatase inhibitor for treatment of breast cancer RN 566-48-3 MF C19H26O3 MW 302.41 CN 4-hydroxyandrost-4-ene-3 17-dione androst-4-ene- 3 17-dione 4 5-epoxyondrostone-3 17-dione Reference Marsh D.A. et al. J. Med. Chem. JMCMAR 28 788 1985 . 932 F Formocortal alternative synthesis Mann J. Pietrzak B. J. Chem. Soc. Perkin Trans. 1 JCPRB4 1983 2681. Burnett R.O. Kirk D.N. J. Chem. Soc. Perkin Trans. 1 JCPRB4 1973 1830. Brodil A.M. et al. Endocrinology ENDOAO 100 1684 1977 . micronised formcstane EP 346 953 Ciba-Geigi appl. 31.10.1985 CH-prior. 6.11.1984 . stable suspension for injection EP 181 287 Ciba-Geigy appl. 31.10.1985 CH-prior. 6.11.1984 . US 5 002 940 Ciba-Geigy 26.3.1991 appl. 31.10.1985 CH-prior. 6.11.1984 . medical use for treatment of breast cancer WO 9 010 462 Endorecherche appl. 9.3.1990 USA-prior. 10.3.1989 . medical use for treatment of prostate hyperplasia DOS 3 339 295 Schering AG appl. 15.11.1982 . WO 9 100 731 Endorecherche appl. 5.7.1990 USA-prior. 7.7.1989 . medical use for treatment of gynecomastia US 4 895 715 Schering Corp. 23.1.1990 appl. 14.4.1988 . method for inhibition of estrogen biosynthesis US 4 235 893 A. M. Brodie et al. 25.11.1980 appl. 8.5.1978 . Formulation s amp. 250 mg 2 ml Trade Name s D Lentaron Novartis F Lentaron Novartis GB Lentaron Novartis Pharma Pharma Formocortal .